|
gptkbp:instanceOf
|
gptkb:chemical_compound
gptkb:drug
|
|
gptkbp:approvalYear
|
1993
|
|
gptkbp:approvedBy
|
gptkb:FDA
gptkb:EMA
|
|
gptkbp:ATCCode
|
gptkb:L01BB04
L04AA40
|
|
gptkbp:brand
|
gptkb:Leustatin
gptkb:Mavenclad
|
|
gptkbp:CASNumber
|
gptkb:4291-63-8
|
|
gptkbp:chemicalFormula
|
C10H12ClN5O3
|
|
gptkbp:contraindication
|
pregnancy
renal impairment
active chronic infections
liver impairment
|
|
gptkbp:discoveredBy
|
gptkb:Dennis_A._Carson
|
|
gptkbp:drugClass
|
antineoplastic agent
immunosuppressant
|
|
gptkbp:eliminationHalfLife
|
5.6–19.7 hours
|
|
gptkbp:excretion
|
renal
|
|
gptkbp:firstDescribed
|
1970s
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Cladribine
|
|
gptkbp:KEGGID
|
D00268
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
purine analog
inhibits DNA synthesis
|
|
gptkbp:MeSH_ID
|
D015242
|
|
gptkbp:metabolism
|
hepatic
|
|
gptkbp:molecularWeight
|
285.684 g/mol
|
|
gptkbp:origin
|
synthetic
|
|
gptkbp:pregnancyCategory
|
contraindicated
|
|
gptkbp:PubChem_CID
|
2019
CHEMBL1387
DB00242
|
|
gptkbp:routeOfAdministration
|
oral
intravenous
|
|
gptkbp:sideEffect
|
gptkb:lymphopenia
fever
nausea
headache
infections
|
|
gptkbp:synonym
|
gptkb:2-chlorodeoxyadenosine
2-CdA
|
|
gptkbp:UNII
|
8M6C7MNC8G
|
|
gptkbp:usedFor
|
gptkb:hairy_cell_leukemia
multiple sclerosis
|
|
gptkbp:year_of_EMA_approval
|
2017
|
|
gptkbp:bfsParent
|
gptkb:默克
|
|
gptkbp:bfsLayer
|
5
|